Private equity firms Casdin Capital and Viking Global completed a $250m investment in Fluidigm, a biotechnology company. “This investment is the culmination of our Board’s comprehensive review of a wide range of options to maximize stockholder value. Casdin and Viking are leading investors with proven records of partnering with life sciences and biotechnology-focused companies to drive growth, scale, financial performance and value creation. This significant capital infusion and strategic initiative will not only strengthen our balance sheet but accelerate growth and innovation to create significant value for all stakeholders," Carlos V. Paya, Fluidigm Chairman.